Last reviewed · How we verify
extract from Angelica archangelica leaf
extract from Angelica archangelica leaf is a Small molecule drug developed by SagaNatura. It is currently in Phase 2 development.
At a glance
| Generic name | extract from Angelica archangelica leaf |
|---|---|
| Sponsor | SagaNatura |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- NOGO for an Overactive Bladder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- extract from Angelica archangelica leaf CI brief — competitive landscape report
- extract from Angelica archangelica leaf updates RSS · CI watch RSS
- SagaNatura portfolio CI
Frequently asked questions about extract from Angelica archangelica leaf
What is extract from Angelica archangelica leaf?
extract from Angelica archangelica leaf is a Small molecule drug developed by SagaNatura.
Who makes extract from Angelica archangelica leaf?
extract from Angelica archangelica leaf is developed by SagaNatura (see full SagaNatura pipeline at /company/saganatura).
What development phase is extract from Angelica archangelica leaf in?
extract from Angelica archangelica leaf is in Phase 2.